Logo

Biohaven's Nurtec ODT (rimegepant) Receives the US FDA's Approval for Treatment of Migraine

Share this

Biohaven's Nurtec ODT (rimegepant) Receives the US FDA's Approval for Treatment of Migraine

Shots:

  • The approval is based on the P-III OLE trial involves assessing Nurtec ODT (rimegepant- 75 mg) vs PBO in patients with episodic migraine who experience less than 15 headache days/mos.
  • The 1EPs & 2EPs of the trial demonstrate a reduction in monthly migraine days by 4.3 days/mos. after 3mos. treatment- 50% patients reported at least >50% reduction in moderate-to-severe migraine days /mos.- 95% of all US migraine patients experience less than 15 headache days/ mos.
  • Nurtec ODT (rimegepant) is the first and only CGRP receptor antagonist approved by the FDA for migraine as a dual therapy for both the acute and preventive treatment

  Ref: PR Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions